Photo - Geneyx
46227

Geneyx

COVID-19 research consortium

Israel
Market: Medicine, Pharmacology
Stage of the project: Idea or something is already done

Date of last change: 14.04.2020
Rating
equalizer from 2000
help
Calculated and estimated occupancy of the project (more about ratings)
My rating
1
2
3
4
5
6
7
8
9
10
Average rating:

Idea

Whole Genome Sequencing Variant Analysis and Interpretation for COVID 19 Patients. Do carriers of certain variants increase or decrease the expression levels, and in turn, contribute to the sensitivity or resistance to the virus? In the context of the novel coronavirus, SARS-Cov-2, variants that lead to susceptibility to or resistance to infection may prove to be useful to determine prognosis and triage of patients that are infected and might even be the target of tailored treatment.

Current Status

production V-1 is ready, the Analysis module installed in more than 20 customers in 12 countries

Market

In the throes of the COVID-19 outbreak, individuals and governments worldwide are turning to science for answers.
The last global outbreak to cause this much panic was the Spanish flu, which is estimated to have killed 50 million and infected 500 million people between 1918 and 1919. The cause of that disease was at the time unknown. By contrast, the viral agent of COVID-19 was discovered just weeks after the outbreak was first detected in China in December 2019. The genome sequence of the virus was made publicly available, allowing hundreds of projects to begin searching for a preventative vaccine. Potential curative drugs could also be considered based on the knowledge of viral structure that the genome sequence yielded and one, remdesivir, is showing promise in trials in China and the US.

Problem or Opportunity

Platforms for harmonizing and analyzing data as it is generated on patients in various locations and facilities together with consistent informed consent, IRB, and sample collection protocols.

The research - look for informative common polymorphisms, protective loss-of-function mutations, and other genetic factors that may coincide with individuals' propensity for SARS-CoV-2 infection or progression.

Solution (product or service)

We propose to use Illumina based next-generation sequencing (NGS) to perform whole-genome sequencing on cases of individuals severely affected by the novel coronavirus SARS-CoV-2 causing COVID-19 disease and compare them to asymptomatic, mildly affected or moderately affected controls to discover risk and protective variants associated with this infectious disease that is rapidly spreading in the global population.

Competitors

Centogene, CeGAt, Colors, Nebula genomics,

Advantages or differentiators

it is a technical advantage that creates business solution:
Geneyx is the only Genetic software suite that provides labs with ‘Dragen inside’ solution and with Weizmann institute's GeneCards Knowledgebase, plus unlimited secure storage and sharing option. the quality of the solution allows us to aggregate priceless genetic- clinical data sets, for the scientific, Pharma companies

Finance

1. A fully deployed platform, all 4 modules in full operating status:
a. Data b. Analysis c. Apps g. Research
2. 20 SaaS paid labs fully deployed our platform worldwide.
3. Pilot underway, in Europe, the US and China, and building local-based traction
4. 5OK Exome based complete cases and 10K Whole Genome complete cases in storage.
5. Pharma company customers

Business model

Geneyx offers the genetic lab, four modules, DATA- to collect the raw sequenced data directly from the sequencer, running customized pipe-line, or a “Dragen inside” proprietary seamless solution, The Geneyx Analysis- analyze and interpret, the sequenced genome, knowledge-based using “Gene-Cards”. Apps - Off the shelf’ CLIA/CAP – ready tests and reports. Research- Access to high quality, secured and diverse data with the freedom to operate and unlimited computation capabilities. Enabling worldwide research collaboration

Money will be spent on

1. A fully deployed platform, all 4 modules in full operating status:
a. Data b. Analysis c. Apps g. Research
2. 20 SaaS paid labs fully deployed our platform worldwide.
3. Pilot underway, in Europe, the US and China, and building local-based traction
4. 5OK Exome based complete cases and 10K Whole Genome complete cases in storage.
5. Pharma company customers

Offer for investor

Equity

Team or Management

Risks

Regulations
GDPR/ HIPAA

Incubation/Acceleration programs accomplishment

We are participating in
https://gin-austria.com/programs/goAustria

Won the competition and other awards

We won 3 grants from Israel Innovation Authority
We Won pitch night by Next leap ventures

Invention/Patent

Raw genetic data anonymization encryption for HIPPA/GDPR complying storage.
TGex - The GeneCards Suite-powered end-to-end NGS analysis and interpretation platform
TOVANA Health (partner) - Whole Exome / Whole-genome CLIA/CAP approved tests and clinical reporting product (DNA UNLOCK)

Photos

Photo 1 - COVID-19 research consortium

Product Video

5,00
1
2
3
4
5
1 voice
Sign in/Sign up
arrow_back
EN
more_horiz
close
visibility114
star0
Add to favorites
Delete from favorites
share
close
thumb_up0
Like
Unlike
Idea
Current Status
Market
Problem or Opportunity
Solution (product or service)
Competitors
Advantages or differentiators
Finance
Invested in previous rounds, $
Business model
Money will be spent on
Offer for investor
Team or Management
Mentors & Advisors
Lead investor
Risks
Incubation/Acceleration programs accomplishment
Won the competition and other awards
Invention/Patent
Photos
Product Video